Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by mining4dollarson Apr 18, 2013 2:04pm

163 Views

Post# 21297523

spoke with management today...

seems like after a few months of complete and utter silence there should be SIGNIFICANT news flow expected over the next few weeks. Everything from updated year end financials(will be good to see how many warrants were exercised) in the next week or so, and MOST importantly, an update on 007 Phase 2 clinical trial. Also expected is an update on 008.

I got the sense that there is currently a lot going on behind the scenes at the moment and I think we shall all be rewarded for our patience over the coming weeks.

Bought more today as things now finally seem to be ramping up

Bullboard Posts

The investment impact of the U.S. 25% tariff on Canadian imports